The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

Kennedy junior, a vaccine skeptic, hand-picked eight new members for the panel ...

An educational program on the appropriate treatment for RSV infections was conducted for attending physicians and medical residents with multiple methods and forums during the 1994-95 RSV season ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers. The ...

Key takeaways: The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike nirsevimab, which has weight-based dosing, clesrovimab has a fixed dose.

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine. What to know.

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, according to the United Nation health body The World Health Organisation (WHO ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) and AstraZeneca (AZN). Read more here.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...

Clesrovimab-cfor provides a fixed 105-mg dose, simplifying administration and offering five months of protection against RSV in infants. The CLEVER trial demonstrated a 60.5% reduction in RSV ...